Pucotenlimab
- Generic Name
- Pucotenlimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2403647-03-8
- Unique Ingredient Identifier
- CGA81G3KR5
- Background
Pucotenlimab is a recombinant humanized anti-PD-1 monoclonal antibody. It received its first global approval in China in July 2022 for the treatment of solid tumours. It is being investigated in other cancers.
- Indication
用于治疗微卫星高度不稳定╱错配修复缺陷(MSI-H/dMMR)实体瘤的患者，包括既往经过氟尿嘧啶类、奥沙利铂和伊立替康治疗后出现疾病进展的晚期结直肠癌患者；既往至少一线治疗后出现疾病进展且无满意替代治疗方案的其他晚期实体瘤患者。
- Associated Conditions
- -
- Associated Therapies
- -
Biotech Breakthrough: A New Hope for Cancer Treatment? Shocking IPO Plans Revealed!
HanX Biopharmaceuticals plans Hong Kong IPO to fund HX009, a bispecific antibody targeting PD-1 and CD47 for cancer therapies. The company aims to advance HX009 through phase 2 trials for biliary tract cancer and secure FDA approval for U.S. testing. HanX also has a robust pipeline including HX301 for glioblastoma and HX044 for PD-1 resistant tumors. Financial stability from Pucotenlimab sales supports their ambitious goals.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath